Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

NCT ID: NCT05356039

Last Updated: 2022-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-19

Study Completion Date

2028-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter pragmatic prospective observational study including Nordic hospitals treating patients with borderline resectable and locally advanced pancreatic cancer. Eligibility will be assessed at regional multidisciplinary tumor boards. Patients with borderline resectable and locally advanced (non-endocrine) pancreatic cancer according to the National Comprehensive Cancer Network (NCCN) and the International Study Group of Pancreatic Surgery (ISGPS) are eligible for inclusion. The study is observational. Quality of life will be assessed in all study participants. The primary outcomes are exploration rates, resection rates and overall survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreas Cancer Pancreas Neoplasm Pancreas Disease Pancreas Adenocarcinoma Surgery Chemotherapy Effect Quality of Life Locally Advanced Pancreatic Adenocarcinoma Borderline Resectable Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed or suspected invasive pancreatic primary tumor
* Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines

Exclusion Criteria

* Suspected endocrine tumor
* Suspected non-pancreatic periampullary tumor
* Distant metastasis
* Age \< 18 years
* Patient unable to understand verbal or written information interfering with informed consent or treatment
* Mental or organic disorder interfering with informed consent or treatments
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Linkoeping

OTHER

Sponsor Role collaborator

Lund University Hospital

OTHER

Sponsor Role collaborator

Sahlgrenska University Hospital

OTHER

Sponsor Role collaborator

Karolinska University Hospital

OTHER

Sponsor Role collaborator

University Hospital, Umeå

OTHER

Sponsor Role collaborator

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Surgical Clinic at Umeå University Hospital

Umeå, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Oskar Franklin, MD/PhD

Role: CONTACT

+46730458558

Agneta Karhu

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Oskar Franklin, PhD

Role: primary

+4690785000

Agneta Karhu

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UmU-square

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.